Latest News
-
Gold Prices In US: Yellow Metal Rates Surge Amid Escalating Tensions In Middle East; Hit Record High -
Jio Financial Services Sees 80% YoY Decline In Q4 Net Profit, Net Interest Income Dives 70% -
Rs 25/Share Dividend Payout: Multibagger Small Cap Tata Stock Declares 52.6% Jump In Q4 PAT -
Wipro Q4 Results: Cons PAT Up 5% QoQ To Rs 2,834.6 Crore, Revenue Guidance Weaker Than Estimates -
How To Apply Your Voter ID Card Online: Quick Guide For Indian Citizens -
Emmforce Autotech IPO Debut April 23: Issue Size, Price Band, Check Details? -
1:5 Stock Split: PSU Bank Fixes Record Date For First Ever Stock Split; Buy For Rs 650-680 Targets -
Closing Bell: Market Stages Smart Recovery, Sensex & Nifty Snap 4-Day Losing Streak Led By HDFC Bank -
Hindustan Zinc's Quarterly Profits Dive 21% Amid Global Metal Price Slump, Shares Plummet; Buy Or Not? -
IRFC, RVNL, IRCTC, Railtel: Railway Stocks In Focus As Election Polls Begin; Mega Rs 10-12 Lakh Crore Plan
Pfizer India Q1 Profit Declines 83% To Rs 33 Crore, Revenue Falls 21%
Drug firm Pfizer on Friday reported 83 per cent decline in consolidated net profit at Rs 33 crore for June quarter 2022-23, according to a PTI report.
Drug firm Pfizer on Friday reported 83 per cent decline in consolidated net profit at Rs 33 crore for June quarter 2022-23, according to a PTI report. The company had logged a net profit of Rs 200 crore in April-June period a year ago.
Revenue from operations declined to Rs 593 crore in the quarter from Rs 749 crore in the year-ago period. The drug firm said exceptional items for June quarter comprised Rs 130 crore on account of a voluntary retirement scheme and Rs 6 crore for restructuring to drive business transformation.
Shares of the company settled at Rs 4,230 apiece, down 0.72 per cent, on the BSE.
Pfizer was listed on the Bombay Stock Exchange in 1966. Today it has more than one lakh shareholders in India. With annual sales of over Rs 2000 crores, it is the fourth largest multinational pharmaceuticals company in India. The company has a portfolio of more than 150 products across 15 therapeutic areas.
